Blog

■ Subclinical left ventricular dysfunction during chemotherapy

Martin Nicol, Mathilde Baudet, Alain Cohen-Solal

Card Fail Rev. 2019 Feb; 5(1): 31–36

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6396067/

 

■ Common risk factor for heart failure and cancer

Wouter C Meijers, Rudolf A de Boer

Cardiovasc Res. 2019 Apr 15; 115(5): 844–853

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6452432/

 

■ Enfermedades cardiovasculares y cáncer: dos entidades mutuamente relacionadas?

Mendoza-Torres, Evelyn et al.

Rev Chil Cardiol, Abr 2019, vol.38, no.1, p.54-63

https://scielo.conicyt.cl/scielo.php?script=sci_arttext&pid=S0718-85602019000100054&lng=es&nrm=iso

 

■ Cancer therapy-related cardiac dysfunction: an overview for the clinician

Irving E Perez, Sara Taveras Alam, Gabriel A Hernandez, Rhea Sancassani

Clin Med Insights Cardiol. 2019; 13: 1179546819866445

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6664629/

■ Common risk factors for heart failure and cancer

Wouter C Meijers, Rudolf A de Boe

Cardiovasc Res. 2019 Apr 15; 115(5): 844–85

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6452432/

 

■ AF (atrial fibrillation) in cancer patients: a different need for anticoagulation?

Ana Pardo Sanz, José Luis Zamorano Gómez

Eur Cardiol. 2019 Apr; 14(1): 65–6

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6523059/

 

■ Management of atrial fibrillation in patients taking targeted cancer therapies

A Asnani, A Manning, M Mansour et al

Cardio-Oncology 2017: vol 3: 2

https://cardiooncologyjournal.biomedcentral.com/articles/10.1186/s40959-017-0021-y

 

■ The evolving design of NIH-Funded cardio-oncology studies to address cancer treatment-related cardiovascular toxicity

L M Minasian, E Dimond, M Davies et al

JACC: CardioOncology 2019, vol 1 (1)

https://cardiooncology.onlinejacc.org/content/1/1/105

 

■ 5-FU induced cardiotoxicity: case series and review of the literature

C Yuan, H Parekh, C Allegra et al

Cardio-Oncology 2019, vol 5:13

https://cardiooncologyjournal.biomedcentral.com/articles/10.1186/s40959-019-0048-3

 

■ Cardio-oncology: an overview on outpatient management and future developments

1. J. Teske, M. Linschoten, J. A. M. Kamphuis, W. R. Naaktgeboren et al

Neth Heart J. 2018 Nov; 26(11): 521–532

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6220023/

 

■ Cardiovascular imaging in cardio-oncology

Amir Abbas Mahabadi, Christoph Rischpler

J Thorac Dis. 2018 Dec; 10(Suppl 35): S4351–S4366

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6328388/

 

■ Cardio-oncology: a focus on cardiotoxicity

Athanasios Koutsoukis, Argyrios Ntalianis, Evangelos Repasos et al

Eur Cardiol. 2018 Aug; 13(1): 64–69

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6159462/

 

■ Cardiovascular disease and breast cancer: Where these entities intersect: A Scientific Statement From the American Heart Association

Laxmi S. Mehta, Karol E. Watson, Ana Barac et a

Circulation. 2018 Feb 20; 137(8): e30–e66

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6722327/

 

■ Metabolic disorders in heart failure and cancer

Alessia Lena, Andrew J.S. Coats, Markus S. Anker

ESC Heart Fail. 2018 Dec; 5(6): 1092–1098

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6300808/

 

■ Comprehensive review of cardiovascular toxicity of drugs and related agents

Přemysl Mladěnka, Lenka Applová, Jiří Patočka et al

Med Res Rev. 2018 Jul; 38(4): 1332–140

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6033155/

 

■ Cardio-oncology related to heart failure common risk factors between cancer and cardiovascular disease

Anne Blaes, Anna Prizment, Ryan J. Koene, Suma Konet

Heart Fail Clin. 2017 Apr; 13(2): 367–380

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5547738/

 

■ Cancer and heart failure: understanding the intersection

Carine E Hamo, Michelle W Bloom

Card Fail Rev. 2017 Apr; 3(1): 66–70

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5494160/

 

■ Cardiotoxicity following cancer treatment

GM Walls, AR Lyon, MT Harbinson, GG Hanna

Ulster Med J. 2017 Jan; 86(1): 3–9

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5324172/

 

■ CardioOncologia Online (Cardio-Oncology) no Blog Internet Médica

https://internetmedica.com.br/cardiooncologia-online-cardio-oncology/

 

■  Dr Paulo Fernando Leite

Cardiologia/Prevenção Cardiovascular

Estratificação de Risco Cardiovascular

Consultório: Rua Padre Rolim 815/sala 601

Tel: 33245518

CRMMG: 7026

Email: pfleite1873@gmail.com

Data: out 2019

■ CMAJ – Canadian Medical Association Journal

Serie Five Things to Know About

 

■ Diagnosing ovarian cancer

Melissa Walker, Mara Sobel

CMAJ. 2018 Oct 22; 190(42): E125

1 – Early-stage ovarian cancer is difficult to diagnose because presenting symptoms are vague and nonspecific

2 – Transvaginal ultrasonography is the initial imaging modality for women with symptoms of ovarian cancer

3 – Serum tumours markers can be helpful when a complex ovarian cyst is identified

4- The RMI II can be used in primary care to identify women requiring urgent assessment

5 – Women with a strong family history of breast, ovarian or colon cancer should be referred to a genetic counsellor

 

■ Adnexal torsion: Five Things to Know About Online

Jessica Papillon-Smith, Mara Sobel

CMAJ. 2018 Jun 25; 190(25): E769.

1 – Adnexal torsion should be considered in women of all ages with acute abdominopelvic pain

2 – Signs and symptom are often nonspecific

3 – Transvaginal ultrasonography is the imaging modality of choice to asses the adnexae

4 – Adnexal torsion is a surgical emergency

5 – At surgery, the affected ovary should be preserved

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6019344/

 

■ Retained intrauterine devices in pregnancy: Five Things to Know About Online

Ari P. Sanders, Barry H. Sanders

CMAJ. 2018 Apr 9; 190(14): E440

4 – In North America, 5%-10% of reproductive-aged women use an intrauterine device for contraception

2 – Pregnancies are at increased risk of adverse outcomes with a retained IUD

3 – Current evidence supports removal of retained IUDs in pregnancy

4 –There are procedures to remove intrauterine devices in pregnancy when the strings are not visible

5 – When pregnancy continuation is desired, retained IUDs should be removed at the earliest gestational age possible

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5893319/

 

■ Prepubertal vulvovaginitis: Five Things to Know About Online

Emily P A Brander, Sarah K McQuillan

CMAJ 2018, vol 190 (26): E800

1 – Inflammation and irritation of the lower genital tract, or vulvovaginitis, is common in prepubertal girls

2 – Common presenting symptoms include pruritus, discharge, discomfort and dysuria

3 – About 25% of vulvovaginitis cases in children are caused by infections

4 – Recurrent symptoms, associated with a foul smell, may be due to a foreging body in the vagina

5 – Psoriasis, atopic dermatitis and linchen sclerosus may cause chronic vulvar dermatosis

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6028267/

 

■ Mifepristone: Five Things to Know About Online

Sheila Dunn, Melissa Brooks

CMAJ. 2018 Jun 4; 190(22): E688

1 – Mifepristone, the drug for medical abortion, became available in Canada in January 2017

2 – Combined mifepristone and misoprostol is safe and highly effective

3 – There are few contraindications for using mifepristone

4 – Mifepristone abortion can be provided in primary care

5 – Many government insurance plans cover mifepristone and misoprostol

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5988520/

 

■  Dr Paulo Fernando Leite

Cardiologia/Prevenção Cardiovascular

Estratificação de Risco Cardiovascular

Consultório: Rua Padre Rolim 815/sala 601

Tel: 33245518

CRMMG: 7026

Email: pfleite1873@gmail.com

Data: out 2019